Date: 2012-05-15
Type of information: R&D agreement
Compound: new Affilin® therapeutics to treat various diseases
Company: Scil Proteins (Germany) Ono Pharmaceutical (Japan)
Therapeutic area: undisclosed
Type agreement: R&D
Action mechanism: Affilin® therapeutics are based on the small human serum protein, Ubiquitin. They bind targets with high affinity and specificity, have a low immunogenic potential, allow rapid preclinical development cycles and make use of the endogenous Ubiquitin system.
Disease: undisclosed diseases
Details: Scil Proteins GmbH, a private biotech company specializing in the research, development and production of recombinant proteins, has signed a collaboration agreement with Ono Pharmaceutical Co., Ltd. (Osaka, Japan), for the joint discovery and development of new Affilin® therapeutics to treat various diseases. Initially, Scil Proteins will identify and select Affilin® molecules directed against certain target(s) provided by Ono. Under the terms of the agreement, Scil Proteins will select and characterize Affilin® candidates from the Company’s proprietary libraries for further development and commercialization by Ono. By entering this collaboration, both parties expect to fully exploit the therapeutic potential of Affilin® molecules, highly stable ubiquitin-based proteins that bind targets with high affinity and specificity, and low immunogenicity.
Financial terms: In addition to research funding, Scil Proteins will receive milestone payments for research, development and commercialization and is eligible for royalties.
Latest news:
